Revision: Feb. 18, 2026, 2:30 p.m.
Senate Health and Human Services
February 18, 2026
2026-0836s
05/07
Amendment to SB 455-FN
Amend the title of the bill by replacing it with the following:
AN ACT relative to coverage for GLP-1 medication under the state Medicaid plan.
Amend the bill by replacing section 1 with the following:
1 New Section; State Medicaid Plan; GLP-1 Medication. Amend RSA 167 by inserting after section 3-m the following new section:
167:3-n State Medicaid Plan; GLP-1 Medication.
I. Medical assistance under the state Medicaid plan shall include coverage for GLP-1 medication if a health care provider licensed in the state of New Hampshire has determined that such medication is medically necessary for the patient and the patient meets one or more of the following:
(a) BMI greater than or equal to 30 kg/m² (obesity); or
(b) BMI greater than or equal to 27 kg/m² with at least one weight-related comorbidity, including:
(1) Type 2 diabetes.
(2) Hypertension.
(3) Dyslipidemia.
(4) Obstructive sleep apnea.
(5) Cardiovascular disease.
(6) Prediabetes.
(7) Metabolic dysfunction associated steatotic liver disease.
II. The department of health and human services shall submit to CMS any amendment to the state Medicaid plan necessary for implementation no later than January 1, 2027.
2026-0836s
AMENDED ANALYSIS
This bill directs the department of health and human services to provide coverage for GLP-1 medication under the state Medicaid plan if such medication is medically necessary for a patient based on certain health conditions.